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ABSTRACT 
Placenta, as the sole transport mechanism between mother and fetus, links the 
maternal physical state and the immediate and life-long outcomes of the offspring.  The 
present study examined the mechanisms behind the effect of maternal obesity on 
placental lipid accumulation and metabolism.  Pregnant Obese Prone (OP) and Obese 
Resistant (OR) rat strains were fed a control diet throughout gestation.  Placentas were 
collected on gestational d21 for analysis and frozen placental sections were analyzed for 
fat accumulation as well as β-Catenin and Dkk1 localization.  Additionally, DKK1 was 
overexpressed in JEG3 trophoblast cells, followed by treatment with NEFA and Oil Red 
O stain quantification and mRNA analysis to determine the relationship between 
placental DKK1 and lipid accumulation.  Maternal plasma and placental NEFA and TG 
were elevated in OP dams, and offspring of OP dams were smaller than OR.  Placental 
Dkk1 mRNA content was 4-fold lower in OP placentas, and there was a significant 
increase in β-Catenin accumulation as well as mRNA content of fat transport and TG 
synthesis enzymes, including Ppar-delta, Fatp1, Fat/Cd36, Lipin1, and Lipin3.  There 
was significant lipid accumulation within the decidual zones in OP but not OR placentas, 
and the thickness of the decidual and junctional zones was significantly smaller in OP 
than OR placentas.  Overexpression of DKK1 in JEG3 cells decreased lipid accumulation 
and the mRNA content of PPAR-Delta, FATP1, FAT/CD36, LIPIN1, and LIPIN3.  Our 
results indicate that Dkk1 may be regulating placental lipid metabolism through Wnt-
mediated mechanisms. 
 Additionally, recent studies have suggested that maternal obesity may also 
program early development of non-alcoholic fatty liver disease (NAFLD), rates of which 
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have correlated with the increase in the obesity epidemic.  In the current study, livers of 
OP offspring had significantly increased TG content (P<0.05) and lipid accumulation 
when compared to offspring of OR dams. Additionally, hepatic Dkk1 mRNA content was 
significantly decreased in OP livers when compared to OR (P<0.05), and treating 
H4IIECR rat hepatocyte cells with NEFA showed that Dkk1 mRNA was also decreased 
in NEFA-treated cells (P<0.05) that also had lipid accumulation.  Chromatin 
Immunoprecipitation (ChIP) analysis of the Dkk1 promoter in fetal livers showed a 
pattern of histone modifications associated with decreased gene transcription in OP 
offspring, which agrees with our gene expression data.  These results demonstrate that the 
hepatic Dkk1 gene is epigenetically regulated via histone modification in neonatal 
offspring in the current model of gestational obesity, and future studies will be needed to 
determine whether these changes contribute to excessive hepatic lipid accumulation in 
offspring of obese dams. 
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CHAPTER 1: INTRODUCTION 
 
Significance 
 
The rates of gestational obesity have been increasing at the same rapid rate as the 
obesity epidemic in the general population (1).  These statistics are alarming not only 
because obese pregnancies are accompanied by various birth complications, but also 
because human and animal studies have shown that being obese during pregnancy 
programs offspring for a variety of adult-onset diseases.  The placenta regulates the 
transport of all nutrients between maternal and fetal circulation, and is at a marked risk 
for the accumulation of ectopic fat in instances of obesity during pregnancy.  Although 
the connection between fetal outcomes and maternal obesity has been irrefutably 
established, the molecular mechanisms remain undefined.  As the principal link between 
mother and child, the placenta has become an important factor in unraveling these 
mechanisms (2, 3).  Poor placentation has been associated with Intrauterine Growth 
Restriction (IUGR) as well as Small for Gestational Age (SGA) offspring, gestational 
diabetes, and a risk for the offspring of developing numerous late-onset diseases (4-6). 
The current study focused on the regulation of placental lipogenesis in response to 
gestational obesity in an obesity-prone (OP) rat model.  We hypothesized that placentas 
of OP animals would have an increased lipid accumulation and that this would be 
accompanied by an increase in oxidative stress.  Additionally, because of its involvement 
in vascularization, development, and recent association with adipogenesis, we 
hypothesized that the Wnt pathway has a critical role in placental lipid metabolism.  As 
the primary mode of communication between mother and fetus, the placenta has an 
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integral part in the adaptations that occur in a nutrient-restricted or abundant pregnancy, 
and we aimed to demonstrate that Wnt signaling may be involved in this adaptation.   
Additionally, because the rates of non-alcoholic fatty liver disease have increased 
at the same rapid rate as the obesity epidemic, we propose that maternal obesity will be 
associated with substantial lipid accumulation in livers of offspring of obese dams.  
Because Wnt has also been connected to liver development, we hypothesize that livers of 
offspring born to obese dams will have altered Dkk1 expression, and that this may be due 
to epigenetic modifications of the gene.  The current study contributes novel and 
substantial knowledge to the study of placental lipid metabolism as well as hepatic lipid 
accumulation in neonatal offspring in response to the growing obesity epidemic, and 
clearly understanding the consequences of obesity during pregnancy is imperative, as it 
may lead to significant changes in the current pre-pregnancy weight recommendations.  
 
Specific Aims 
The proposed hypotheses were tested by pursuing the following specific aims: 
Specific Aim 1:  
Determine the consequences of gestational obesity on placental physiology, with a 
principal focus on placental lipid accumulation and metabolism. 
 
We hypothesized that maternal obesity will result in increased lipid accumulation as well 
as oxidative stress, and this will be associated with changes in maternal circulating lipids.  
Additionally, we proposed that placental structure will be altered in OP placentas, and 
that genes related to placental fatty acid uptake and metabolism will be increased. 
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Specific Aim 2:  
Determine the events occurring within the placental canonical Wnt signaling pathway in 
response to gestational obesity and investigate the potential role of this pathway in 
placental lipid metabolism.  
 
We hypothesized that OP placentas would have a disregulation in canonical Wnt 
signaling, and that these changes would be directly associated with altered placental lipid 
metabolism. 
 
Specific Aim 3:  
Determine the consequences of gestational obesity on hepatic lipid accumulation and 
Dkk1 mRNA expression in neonatal offspring. 
 
We hypothesize that offspring of obese dams will have an increase in lipid accumulation, 
and this will be associated with a change in hepatic Dkk1 mRNA expression, potentially 
due to histone modifications within the promoter of the gene. 
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CHAPTER 2: LITERATURE REVIEW 
 
Common Rodent Models of Obesity and Complications of Maternal Obesity  
Common Rodent Models of Obesity 
 The model of obesity-proneness and resistance has been thoroughly studied and 
characterized and is a valuable tool for modeling obesity and metabolic syndrome in the 
human population.  The earliest studies of rats that tended to either gain weight or were 
resistant to weight gain on a high-fat (HF) diet (60% of calories from fat) showed that 
after 4 weeks on the HF diet, obesity prone (OP) rats ate more than obesity resistant (OR) 
animals, had lower insulin sensitivity, higher plasma free fatty acids (FFA), as well as a 
higher respiratory quotient, suggesting that OP animals oxidized a higher proportion of 
fat than OR (7).  Additionally, after 2 or 7 months of either HF or low-fat (LF) feeding, 
OP rats remained heavier and fatter than the LF diet controls after 2 months, and after 
food restriction, their body weight and body energy content stabilized at a higher level 
than the LF controls, suggesting that these animals were defending their adiposity.  After 
refeeding, OP rats regained their obese state (8).  When muscle metabolism was 
compared between OR and OP rats, insulin-stimulated glucose uptake and oxidation was 
significantly lower in OP rats, as was glycogen storage.  Although OP rats gained 60% 
more body weight than OR, they ate only 10% more energy than OR (9).  Further 
analysis of lipid metabolism differences between OR and OP rats showed that after 5 
weeks on the HF diet, fat pad weights were significantly heavier in OP rats, while the 
FFA rates of appearance and oxidation were not different between OR and OP rats.  
However, glycerol rates of appearance and intracellular FFA were significantly elevated 
in OP rats (10).  Later studies showed that OP rats can be characterized by an increase in 
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plasma TG (11) and have reduced capacity for fatty acid oxidation (12), especially in the 
liver (13).  Barry Levin’s group was instrumental in selectively breeding the obesity 
phenotype out of the Sprague-Dawley strain (14), and their interest was primary in the 
brain differences between OR and OP rats.  They found that OP rats had increased 
glucose-induced norepinephrine release (15), but the turnover of norepinephrine, an index 
of sympathetic activity, was significantly decreased in the heart, pancrease, and 
hypothalamus (16).  Additionally, they showed that OP rats have decreased leptin 
sensitivity (17, 18), are more sensitive to stress-induced weight gain (19), have 
inappropriate insulin signaling (20, 21) and beta-cell mass with age (22), and defend their 
body weight in response to exercise (23), potentially because of their altered energy 
expenditure (24).  While there are still many unknowns in this model of obesity 
development, it appears that these rats have many of the characteristics of humans who 
are obese, which makes this an appropriate model for the current study.       
 
Current Gestational Weight and Weight Gain Recommendations 
In a 2009 response to the growing obesity epidemic, especially in women of 
childbearing age, the American Dietetic Association (ADA) issued a statement focusing 
on maternal obesity and weight gain (25).  The ADA statement asserted that all obese and 
overweight women of reproductive age should receive nutrition and diet counseling prior 
to pregnancy, during pregnancy, and after pregnancy to alleviate the adverse outcomes of 
being obese during pregnancy.  This statement from the ADA also reviewed the current 
weight and weight gain recommendations for all women, focusing on the obese and 
overweight population.  Specifically, it was suggested that pre-pregnancy weight loss is 
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the best recommendation for obese women.  However, weight loss is difficult, and 
restrictive eating or dieting before and during pregnancy may be detrimental to maternal 
and fetal health.  Therefore, it has been stated that the most realistic interventions should 
occur during the time of pregnancy, when women are most likely to make changes to 
guarantee fetal health.  The primary intervention is to urge women to gain within the 
Institute of Medicine (IOM) 1990 guidelines for each pre-pregnancy BMI (15-25 lb for 
BMI>26-29, 15 lb for BMI>29).  Since this statement was published, the IOM updated its 
recommendations to prescribe a 15-25 lb weight gain for overweight women (BMI=25-
29.9), and a gain of 11-20 lb for obese women (BMI≥30.0) (26). 
 
Consequences for the Mother  
The World Health Organization (WHO) predicts that in the United States, one-
third of women of reproductive age are classified as obese, and the IOM recently reported 
that since the mid-1990s, about half of women of childbearing age are overweight (27, 
28).  Historically, maternal and gestational obesity has been discouraged because of its 
effect on maternal and immediate fetal health, as obese pregnancies are often complicated 
by gestational diabetes, preeclampsia, macrosomia and cesarean section (29).  Normal 
pregnancy is a time of weight gain, but the weight gained in normal-weight mothers is 
quite different than in obese women.  Because of the metabolic shift that occurs in obese 
individuals, studies have shown that obese women tend to gain weight more centrally 
than lean women.  This central-visceral adiposity has been associated with the negative 
outcomes described above, including gestational diabetes, hypertension, pre-eclampsia, 
and insulin resistance (30-33).  An analysis of 151,025 Swedish women found that the 
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risk of pre-eclampsia, gestational hypertension, gestational diabetes, cesarean delivery, 
stillbirths, and large-for-gestational age births was increased during the second 
pregnancies of women who experienced an increase in BMI score of 3 or more between 
their first and second pregnancies (34).  Obese women have a decrease in HDL 
cholesterol, together with a severe increase in plasma triglycerides and total cholesterol 
(35).  Additionally, the normal pregnancy-associated insulin resistance is exacerbated in 
women who are obese during pregnancy, increasing the risk for gestational diabetes (36, 
37). 
 
Short-Term Consequences for the Fetus 
The immediate short-term effects of maternal BMI on the offspring were recently 
assessed through a metanalysis, where it was shown that as maternal BMI increased, so 
did fetal compromise, meconium, shoulder dislocation, and NICU use.  There was also a 
decrease in Apgar scores in neonates of obese mothers (38).  Other studies have shown 
that gestational obesity is associated with stillbirth, neonatal death, and other severe fetal 
complications (39, 40).  Data related to the effect of maternal obesity on fetal birth 
weight are contradictory.  Because gestational obesity is associated with an increase in 
fuel availability to the fetus in the form of glucose, it has been believed that maternal 
obesity and macrosomia are strongly associated.  However, recent studies have shown 
that maternal obesity in humans and animals can also be accompanied by low fetal birth 
weights and IUGR (41-44).   
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Long-Term Consequences for the Offspring 
The idea of in-utero programming of adult-onset disease has become of increasing 
interest in the scientific community.  Numerous epidemiological studies have shown that 
the uterine environment has a predictive effect on the long-term health of offspring (45-
48). These studies have focused on the programming of obesity, hypertension, insulin 
resistance and heart disease, and are supported by numerous animal studies showing the 
effects of maternal obesity on the weight, adiposity, insulin resistance and health of 
offspring in adulthood (29, 49).  Additionally, recent studies have suggested that maternal 
obesity may also program early development of non-alcoholic fatty liver disease 
(NAFLD) (42, 50, 51), rates of which have been correlated with the increase in the 
obesity epidemic (52, 53).  Table 2.1 provides a review of current data related to 
maternal obesity and offspring outcomes and Table 2.2 focuses on obesity development 
in the offspring of obese mothers (54). 
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Table 2.1:  Consequences of gestational obesity.  Adapted from Ruager-Martin, et al 
(54), refer to the original review for a full list of references.  
 
Factor Conclusion 
Infertility Women with a BMI > 35 are 26–49% less likely to conceive compared to women with BMI of 21–
29. 
Miscarriage and 
still birth 
Women with pre-pregnancy obesity have an odds ratio for late antepartum death ranging from 2.4 to 
3.1 when compared to non-obese women. 
Gestational 
diabetes 
A meta-analysis of 57,000 subjects from 18 cohort studies showed that the odds-ratio of developing 
gestational diabetes increases with increasing BMI, from 3.56 [3.05–4.21 95% CI] in obese women 
to 8.56 [5.07–16.04] in severely obese women, compared to normal weight controls. 
Gestational 
hypertension 
For each unit increase in pre-pregnancy BMI the relative risk for gestational hypertension is 1.09.  
Women with a waist circumference > 80 cm at 16 weeks of gestation had a risk ratio for gestational 
hypertension of 1.8 [1.1–2.9 95% CI] compared to mothers with a waist circumference < 80 cm. 
Pre-eclampsia Approximately 65,000 subjects showed a risk for pre-eclampsia of 2.47 [1.66 to 3.67 95% CI] for 
raised pre-pregnancy BMI.  A systematic review of 13 cohort studies including 1.4 million women, 
showed that the risk of pre-eclampsia almost doubles for every 6 unit increase in pre-pregnancy BMI. 
Delivery 
complications 
Rates of Caesarean section were 20.7% in normal weight mothers, 33.8% in obese mothers and 
47.4% in morbidly obese mothers. 
Maternal death 35% of all of pregnancy-related death involved obese women.  More than half of all the women who 
died from direct or indirect causes during (late) pregnancy or labor were either overweight or obese, 
and more than 15% were morbidly obese. 
Fetal Maternal obesity was associated with a 1.7-fold increased risk of neural tube defects.If the woman 
was severely obese, the risk was increased more than 3 fold.  In a population based study, for every 
incremental unit increase in BMI the risk of birth defects increased by 7%. 
Small for 
gestational age 
A study involving 385 obese nulliparous women found an overall incidence of SGA infants of 18.8% 
(72/382) compared to 10% in the general population. Additionally, stillborn infants born to obese 
mothers are smaller than those born to mothers of normal body weight.  
Fetal overgrowth A correlation between neonatal weight and the mother’s pre-pregnancy BMI has been shown 
(r = 0.20, p = 0.044).  A study of 2329 mother–baby pairs in showed an increase in average birth 
weight with increasing maternal BMI. An adjusted odds ratio for birth weight > 4500 g of 2.0 (1.4–
3.0 95% CI) has been reported in obese, mothers (2.4 (1.5–3.8) in morbidly obese) when compared 
with controls. 
Preterm birth and 
neonatal mortality 
A population based study of 300,000 births showed that delivery before 32 weeks gestation was 
significantly less likely to occur in women with BMI > 30 (OD: 0.73, 95%CI: 0.65–0.82).  Studying 
284 preterm births, mortality increased from 9% (5/53) in babies born to thin mothers, to 47% (8/17) 
in offspring of obese mothers. 
Breastfeeding A population based study of 300,000 births suggested that a BMI > 30 was associated with an odds 
ratio for breast feeding at discharge of 0.86 (95%CI: 0.84–0.88) compared to normal weight mothers. 
Body composition In a study of 216 9-year-old children, for 1 standard deviation increase in maternal prepregnant BMI, 
there was an increase of 0.26 standard deviations in the fat mass index (total body fat (kg) / height 
(m)) of the offspring (obtained using dual x-ray absorptiometry). 
Metabolic effects In a population-based screening of 3 million children, a U-shape relationship was found between 
birth weight and risk of developing type-2 diabetes mellitus in childhood, and mothers of children 
who developed type-2 diabetes had significantly higher BMI than mothers of children without 
diabetes. 
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Table 2.2: Relationship between maternal obesity and the risk of childhood obesity. 
Consequences of gestational obesity.  Adapted from Ruager-Martin, et al (54), refer to 
the original review for a full list of references.  
 
Cohort 
size Follow up age Conclusion 
547 2 years 
Maternal BMI associated with offspring weight at birth, 1 year and 2 years. 
Maternal prepregnancy BMI is correlated with offspring BMI at 2years 
(r = 0.18, p < 0.001) during the first two years of life. After 1 year post-birth 
offspring BMI is also correlated with paternal BMI (at 2 years: r = 0.23, 
p < 0.001). 
8494 4 years The risk of childhood obesity at 4 years is associated with maternal obesity (measured during first trimester; BMI > 30) (OR: 2.3; 95% CI: 2.0–2.6). 
313 5 years 
Children of obese mothers (pre-pregnancy BMI > 30) have 0.54 kg more fat 
mass than children of non-obese mothers as determined by dual-energy x-ray 
absorptiometry. 
4062 5 years 
Pre-pregnancy maternal obesity (≥ 95 percentile) (OR: 4.7; 95% CI: 3.3–6.8) 
and paternal obesity (≥ 95 percentile) (OR: 2.9; 95% CI: 1.9–4.5) are 
independent predictors of severe obesity (≥ 95 percentile) at 5 years. 
3022 2–7 years Maternal pre-pregnancy BMI > 30 associated with an increased odds ratio for overweight in the offspring (OR: 1.37; 95% CI: 1.02–1.84). 
3306 5–7 years 
Children's BMI is significantly correlated with parental BMI, although a closer 
correlation was observed between maternal (r = 0.249; p < 0.01) than paternal 
(r = 0.159; p < 0.01) BMI. Also there was a closer correlation between the BMI 
of boys and parental BMI than that for girls. 
871 7 years Maternal obesity (BMI > 30) results in higher offspring body fat measured by bioelectrical impedance analysis (OR: 4.0 (95% CI: 0.4–7.7). 
1779 7 years Maternal index (kg/cm) is associated with offspring obesity at 7 years of age (p < 0.5). 
8234 7 years Maternal BMI during pregnancy and Paternal BMI are independent predictors of obesity at 7 years (both parents: adjusted OR: 10.44; 95% CI: 5.11–21.32). 
4654 7.5 years Child BMI is associated equally with maternal (r = 0.295 (0.267 to 0.322)) and paternal (r = 0.250 (95% CI: 0.218 to 0.274)) BMI. 
216 9 years For 1 standard deviation increase in maternal pre-pregnancy BMI, fat mass index increased by 0.26 standard deviations. 
2636 2–14 years Maternal pre-pregnancy BMI > 30 associated with an increased odds ratio for overweight in the offspring (adjusted OR: 4.1; 95% CI): 2.6–6.4). 
3340 14 years 
Pre-pregnancy maternal BMI (β 0.353 (95% CI: 0.304–0.401) a stronger 
predictor of offspring BMI than paternal BMI (β 0.251 (95% CI: 0.199–
0.304) (difference between maternal and paternal: p = 0.009). 
1103 18 years Maternal pre-pregnancy BMI is the strongest predictor of offspring obesity (OR: 0.39; 95% CI: 0.28–0.49). 
17,414 33 years Pre-pregnancy maternal BMI explained association between birth weight and adult BMI. 
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Consequences for the Placenta 
As the primary link between the maternal and fetal environments, the placenta has become an 
important focus of studies aiming to uncover the role of maternal obesity in fetal programming 
and immediate health.  Human placental studies are still limited, but several have shown that 
maternal obesity has a significant effect on placental inflammation and oxidative stress (55-57).  
Specifically, they have shown that as maternal BMI increases so do placental nitrative stress, 
oxidative stress, cytokine production, and macrophage accumulation.  Although human research 
related to placental development during obesity is limited, a variety of animal studies and 
outcomes are available.  A recent study utilizing the baboon as the animal model demonstrated 
that maternal obesity leads to an increase in placental macrophages, a decrease in System A 
transporter activity, and that these effects correlated negatively with maternal leptin 
concentrations (58).  Another study, focusing on diet-induced obesity in a pregnant rat model, 
demonstrated that although the placentas of heavier animals did not differ in size when compared 
to the lean rats, the ratio of fetal weight to placental weight was significantly decreased.  These 
results indicated that the placentas of the obese dams were less efficient in supporting fetal 
development than placentas of lean animals (59). 
 
Placental Characteristics 
Placental Function 
The placenta functions as the sole transport mechanism between mother and fetus for all 
essential nutrients and substances, as well as, waste products.  The placenta is responsible for 
transporting oxygen, carbon dioxide, water, and any other essential nutrients.  Respiratory gases 
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pass freely from maternal to fetal blood, as do other lipophilic substances, and their transport 
depends primarily on concentration differences of these substances between mother and fetus.  
Hydrophilic substances, such as ions, amino acids and glucose have poor diffusion capacity 
across the placenta, and require transport proteins and ion channels in order to become available 
to the fetus (60).  The weight of placenta required for adequate fetal development varies across 
species.  The appropriate fetal-to-placental weight ratio in humans is approximately 6:1, while 
rats have a ratio of 10:1 (61).  The rat’s ability to produce more fetus per gram of placenta is 
thought to be due to the rodents’ placental countercurrent blood exchange.  In this arrangement, 
maternal and fetal capillaries are in parallel to each other, and blood flows in opposing directions 
(62).  Humans have the less-efficient multivillous arrangement, resulting in the need for a larger 
placenta (61).   
 
Placentation and Placental Structure 
 In humans, placentation requires an extensive invasion of placental trophoblasts into the 
uterus, and these trophoblastic cells have a wide aray of vital functions, including anchoring the 
placenta to the uterine wall, transporting nutrients and oxygen to the fetus, removing waste 
products, secreting hormones and other placental proteins, and acting as a physical barrier 
between maternal and fetal circulations (63).  Figure 2.1 represents the process of human 
placentation and trophoblast invasion. The diagram on the left represents normal placentation, 
with the appropriate conversion of the spiral arteries of the placental bed to uteroplacental 
arteries by migratory extravillous trophoblast cells.  Trophoblasts invade both the arterial media 
and the endothelium, converting the artery into a wide vessel that can deliver blood to the 
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intervillous space.  During inappropriate placental development (on the right), trophoblast cells 
do not invade adequately, causing the spiral arteries to remain narrow, thus reducing the amount 
of blood flowing to the fetus, and leading to poor fetal growth (63). 
 
Figure 2.1:  Representative image of normal (left) and inappropriate (right) placentation.  In 
normal placentation, the placental spiral arteries are converted to uteroplacental arteries by 
extravillous trophoblast cells, which converts the artery into a wide vessel that can deliver blood 
to the intervillous space.  During inappropriate placentation, trophoblast invasion is inadequate, 
and the spiral arteries are not properly transformed, which disrupts blood flow and causes 
reduced growth of the branches of the placental villous tree.  Adapted from Moffett et al (63). 
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Species differences in placental structure become important when selecting an 
animal model to study placental development and efficiency.  Placentas are most often 
classified using two major factors:  
1) the shape of the placenta as well as the number of contact points between 
mother and fetus, and  
2) the number of tissue layers separating fetal and maternal vascular systems.   
In regards to the first classification, primates and rodents develop a single “discoid” 
placenta, while horses, cats, dogs, pigs and ruminants have alternate placental structures.  
When classifying placentas according to the number of intermediate layers (also known 
as the Grosser Classification), primates and rodents once again fall into the same 
“hemochorial” category.  With this architecture, all pregnancy-associated maternal tissue 
layers are reorganized to become the placenta, eliminating any layers between the 
placenta and fetus, and exposing the fetal chorionic epithelium to maternal blood (61).  
Although the metabolisms of primates and rodents are not identical, the similarities 
between their placental structures make the rat the most appropriate species for modeling 
human placental function and transport capacity.  Figure 2.2 is a visual representation of 
different types of placentas, Figure 2.3 diagrams rodent placentation (top), and a similar 
diagram of human placentation (bottom).  
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Figure 2.2:  Three main types of placentation, showing the relationship between the fetal trophoblast cells and maternal blood.  
In haemochorial placentation (panel C), as seen in humans and rodents, maternal uterine blood vessels are infiltrated by 
trophoblast cells, allowing the release of blood into the intervillous space. Adapted from Moffett et al (63). 
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Figure 2.3:  Rodent placentation (top, adapted from Comparative Placentation [internet 
source], UCSD, Kurt Benirschke) and human placentation (bottom, adapted from Moffett 
et al (63).) 
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Placental Lipid Metabolism 
Because triglycerides (TG) are not transported across the placenta, their 
hydrolysis to free fatty acids (non-esterified fatty acids, NEFA) provides a vital source of 
essential fatty acids for both the placenta and fetus (64).  Additionally, studies have 
shown that placental uptake of free fatty acids from maternal circulation is not a passive 
event, and occurs primarily via transport proteins, such as fatty acid transport proteins 1-6 
(FATP), the plasma membrane fatty acid binding protein (FABP-pm) as well as a fatty 
acid translocase (FAT/CD36) (65).  Once these free fatty acids are taken up, they may be 
oxidized as an energy source for the placenta, transferred directly to the fetus or esterified 
to TG before being delivered to fetal circulation.  Although mechanisms behind placental 
fatty acid metabolism are not thoroughly understood, it has been suggested that nuclear 
receptors, especially the PPARs, that regulate lipid metabolism in other tissues, also 
participate in placental fat metabolism (66).  Because these genes have been shown to be 
key regulators of placental lipid transport, Fatp1 and Fat/CD36 were analyzed in the 
current study.  Additionally, Dgat1, Lipin 1, 2 and 3 were measured as markers of 
triglyceride synthesis, and Ppar-delta as a potential regulator of these events.   
 
Programming of Non-Alcoholic Fatty Liver Disease 
NAFLD has numerous etiologies, but the primary characteristic is the presence of 
fat in the liver, with potential inflammation and fibrosis (67).  Rates of childhood 
NAFLD and the accompanying steatohepatitis are increasing (68), and recent studies 
have shown that maternal obesity may program early development of NAFLD (42, 50, 
51), rates of which have correlated with the increase in the obesity epidemic (52).  An 
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excess of hepatocyte triglycerides (TG) has often been considered as the first and 
hallmark sign of NAFLD development (69), often called the “first hit”, as it is 
accompanied by oxidative stress.  Additional inflammation and fibrosis follow as the 
“second hit” and inevitably leads to excessive cellular liver damage.  Because NAFLD is 
difficult to treat in adulthood and often leads to irreparable liver damage if left untreated, 
the potential programming of this disease during the in utero period confirms the 
importance of maternal health and diet.  
 
Programming Gene Expression Through Histone Modifications 
In utero histone modification in response to changes in maternal physiology or 
nutrition has been demonstrated in a number of studies.  Gestational food restriction in 
rats was shown to affect Igf1 (Insulin-like growth factor) mRNA expression and the 
levels of dimethylation of histone H3 at lysine residue 4 (H3K4Me2) within its promoter 
(70), and gestational protein restriction in mice resulted in a decrease in the mRNA 
expression of Igf2, with a concurrent decrease of H3K4Me3 and H4K20Me3, and an 
increase of H3K9Me3 and H3K27Me3 (71).  In another study, gestational choline 
supplementation led to an increase in H3K9Me2 and H3K27Me2, while choline-
deficiency increased the levels of H3K4Me2 (72) in offspring of rat dams.  The 
consequences of gestational obesity on the histone code have not been thoroughly 
studied.  A recent study in primates, Japanese macaques, showed that chronic 
consumption of a maternal high-fat diet with accompanying obesity development in the 
mother led to an increase in fetal liver TG and NAFLD.  In fetal hepatic tissues, there 
was an increase in H3K14Ac, and a trend of increase in H3K9Ac and H3K18Ac.  There 
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was also a trend of increase in H3K9Me2, H3K9Me3 and H3K27Me3 (73).  These results 
suggest that maternal diet and physiology have the ability to alter fetal chromatin 
structure in primates via covalent histone modifications. 
 
Wnt Signaling 
Function of Wnt Signaling 
While the complexity of the Wnt signaling pathway makes it difficult to assign it a 
singular function, the most common approach to classifying Wnt signaling and function 
has been to assign Wnt components to either the canonical or noncanonical pathways 
(Figure 2.4).  The canonical Wnt Pathway is linked to cell fate determination, while the 
noncanonical Wnt pathway is associated with the control of cell movement and cell 
polarity (74).  Because of its extensive involvement in the control of cell growth, a strong 
connection has been made between canonical Wnt signaling and the progression of 
colorectal cancer (75), as well as bone and eye development (76).  A connection has also 
been made between TCF4 (a Wnt component) and the development of Type 2 Diabetes 
(77), but this relationship is not well-understood. 
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Figure 2.4: Wnt components in the canonical (panel a) or noncanonical (panel b) 
pathways, adapted from Habas, et al (78). 
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Components of Wnt Signaling  
Canonical Wnt signaling is transduced through Frizzled (FZD) receptors and acts 
through the complexing of nuclear β-catenin with the T-cell factor/lymphoid enhancer 
factor (TCF/LEF) family of transcription factors, Legless family docking proteins, and 
PYGO family coactivators to enhance the transcription of target genes (79-84).  
Canonical Wnt signaling occurs following the binding of a Wnt molecule and the 
downstream phosphorylation of Dishevelled (DVL) by Ckiα and its binding to Frat.  The 
subsequent assembly of the FZD-DVL and Lrp5/6-Axin-Frat complexes releases β-
Catenin from Ckiα and Gsk3β phosphorylation and allows it to travel into and 
accumulate in the nucleus (85, 86).   
Noncanonical Wnt signals are also transduced through FZD receptors, but do not 
involve the translocation of β-catenin into the nucleus to induce gene expression.  
Instead, the pathway acts through DVL-dependent small G proteins and c-jun NH2-
terminal kinase (87, 88), as well as Calcium-dependent Nemo-like kinase (NLK) and 
nuclear factor of activated T cells (NFAT) (89, 90). 
Wnt antagonists are either secreted molecules or function at the intracellular level, 
acting through various routes.  Secreted-type inhibitors include Sfrp1, Sfrp2, Sfrp3, 
Sfrp4, Sfrp5, WIF1, Dkk1, Dkk2, Dkk3, and Dkk4 (91).  Members of the Sfrp and WIF 
family members inhibit the binding of Wnt to the FZD receptors, while the Dkk family of 
molecules interact with and causethe endocytosis of LRP5/LRP6 coreceptor to prevent 
the formation of the Wnt-FZD-LRP5/LRP6 complex. 
The complicated nature of Wnt-signaling is confirmed by various reports of 
Wnt’s self-regulation.  Wnt signaling has been shown to feedback-activate Axin2, Dkk1 
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and Nkd, and feedback-inhibit FZD and Lrp6, thereby dampening Wnt-signaling (79, 92, 
93).  Wnt’s feedforward signaling has also been shown to activate Rspo and TCF/LEF to 
activate or reinforce Wnt-signaling (94-96).   
 
Placental Wnt signaling 
Because of its rapid growth and vascularization, it has been proposed that Wnt 
signaling has a vital role in the development of the placenta.  In fact, out of the 19 known 
Wnt ligands, 14 were found in the placenta, and 8 out of the 10 FZD receptors were 
detectable in placental tissue (97).  Numerous studies have explored Wnt-signaling in 
placental tissues and cell culture experiments.  β-Catenin, the key mediator of canonical 
Wnt-signaling, was implicated in trophoblast adhesion, survival and differentiation (98-
100).  Other studies have shown that Wnt7a and TCF/LEF1 are required for 
chorioallantoic fusion (101, 102), and that Wnt2 (103),  Wnt3a (104), Wnt5a, Wnt10b, 
Fzd5 (105),  Sfrp4 (106, 107), Rspo (108, 109) may be essential for proper placental 
vascularization and growth.  Additionally, Dkk1, a potent inhibitor of Wnt-signaling, has 
been shown to be involved in trophoblast invasion and migration (110).  Therefore, it 
appears that many components of the Wnt signaling pathway may have a strong link to 
the poor fetal outcomes associated with inadequate placental development.  While 
numerous studies have shown that Wnt signaling has a vital role in regulating 
adipogenesis and lipid accumulation (111), little is known about the adipogenic action of 
the Wnt signaling pathway in the placenta.  A study in JEG-3 trophoblasts showed that 
the activation of β-Catenin resulted in the increased expression of the StarD7 gene, which 
has been associated with lipid transport (112).  The authors hypothesized that because β-
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Catenin is often associated with proper placental development and vascularization, an 
increase in StarD7 likely results in the appropriate uptake of phospholipids.  However, 
they also noted that excessive StarD7 expression is observed in placental pathologies, and 
that this could be due to the activation of the gene through aberrant β-Catenin signaling.    
 
Hepatic Wnt Signaling 
The Wnt signaling pathway is essential for hepatic cellular proliferation, 
differentiation, survival and metabolism, and thus regulates liver development, stem cell–
assisted regeneration, and zonation (113).  A knockout (KO) of β-Catenin in early 
development resulted in little or no hepatic tissues, and a KO of Wnt2b, a Wnt ligand, 
resulted in delayed liver development (114).  Additionally, in mice, a hepatoblast-specific 
β-Catenin KO was lethal, and was accompanied by undersized livers with little cell 
proliferation and increased proliferation.  These livers also had decreased α-fetoprotein, 
albumin, cyclin-D1, the adherens junction protein E-cadherin, the tight junction protein 
ZO-2, as well as β-catenin targets glutamine synthetase, regucalcin, Egfr, cytochrome 
p450 oxidases Cyp2e1 and Cyp1a2, Glutathione-S-transferase Gsta3, Gsto1, and Gstm1.  
The immature cells also showed elevated oxidative stress, potentially due to a decrease in 
the expression of glutathione-S-transferases (115).  Other than acting as an inhibitor of 
Wnt signaling, the role of hepatic Dkk1 is unclear.  Dkk1 is overexpressed in cases of 
hepatocellular carcinoma (116) with a concurrent decrease in β-catenin, but its expression 
has not been characterized in NAFLD.  In a liver-specific β-catenin KO mouse model 
similar to the one discussed above, mice were fed a control or steatogenic diet, and KO 
mice on both diets had higher hepatic cholesterol levels, and KO mice on the steatogenic 
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diet had significantly higher steatohepatitis and fibrosis when compared with wild-type 
mice .  Therefore, while Wnt appears to be imperative for hepatic development and may 
play a role in hepatic liver metabolism, its activity and the mechanism behind its control 
in fatty livers remain unknown.   
Summary 
 While the dangers of being obese during pregnancy have been confirmed, the 
mechanisms behind these outcomes remain undefined.  A strong link has been 
demonstrated between placental efficiency, maternal physiology and pregnancy 
outcomes.  Additionally, because of its role in cell determination and cycling, the Wnt 
signaling pathway has been designated as a possible determinant of appropriate placental 
development.  The precise action of Wnt signaling in placenta has not been elucidated, 
especially in response to maternal obesity. and despite there existing substantial evidence 
for the role of Wnt in adipose tissue expansion, the role of Wnt in placental lipogenesis 
has not been clearly categorized.  By utilizing a rat model of obesity-prone pregnancy as 
well as a trophoblasic cell culture model, the current study will not only provide vital data 
related to the physiological events occurring in women who are obese during pregnancy, 
but will contribute knowledge to the mechanistic regulation of lipogenesis occurring 
within the placenta in response to gestational obesity.  Moreover, analysis of livers of 
neonates born to obese animals will provide further confirmation of the importance of 
appropriate maternal weight during pregnancy. 
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CHAPTER 3: MATERIALS AND METHODS 
 
Animal Study 
Animal Model and Dietary Treatment  
Timed-pregnant rats were obtained from Charles River Laboratories (Wilmington, 
MA) on gestational day 2.  These rats originated from a line of Crl:CD (Sprague Dawley 
(SD)) rats (Charles River Laboratories strain CD(SD) and substrain Crl) with two lines 
being developed from the outbred colony: the OP(CD) (Obese Prone) become obese 
when fed high-fat diets, and OR(CD) (Obese Resistant) do not become obese when fed 
high-fat diets.  The Charles River company was not helpful in providing information 
regarding the diet fed to the animals before they arrived at our facility, however, after 
reviewing the growth charts available from the company, we concluded that the 25% 
difference in body weight observed upon arrival between the OR and OP animals, they 
were most likely maintained on a standard rodent chow, and not a high-fat diet.  Five 
pregnant rats from each strain group were fed a control diet (Research Diets, Inc, New 
Brunswick, NJ) with the following caloric distribution: 64%CHO, 20%Pro, 16%Fat 
(Table 1) ad libitum until gestational day 20, when they were fasted overnight and 
underwent cesarean delivery to collect placentas.  All placental as well as neonatal liver 
samples were immediately frozen in liquid nitrogen and stored at -80°C for further 
analysis.  Fetal and placental weights were also recorded.  Additionally, trunk blood from 
each dam was collected and immediately spun down to isolate serum and plasma.  Body 
weights were recorded once a week, and food intake data was recorded every 3 days.  
Because these two values were not recorded at the same time and because both food 
intake and body weight stayed consistent throughout pregnancy, the ratio of food intake 
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per gram of body weight was calculated my taking the average daily food intake and 
dividing it by the body weight of dams on d 21 of gestation.  The value for products of 
conception was calculated by adding the weights of all offspring and placentas for each 
dam and then calculating the mean of each group.   
 
Maternal Plasma and Serum Analysis 
To determine plasma TG levels, plasma samples were thawed on ice and analyzed 
via the Thermo Infinity Triglycerides Liquid Stable Reagent (Thermo Fisher Scientific, 
Rockford, IL) following company protocol and using a commercially available standard 
reference kit (Verichem Laboratories, Providence, RI).  Maternal serum NEFA was 
analyzed utilizing a commercially available kit (HR-2 Series, Wako Diagnostics, 
Richmond, VA).  
 
Placental Lipid and Lipid Peroxidation Analysis 
In order to determine whether an increase of circulating TG and NEFA 
corresponds to their increased accumulation within the placenta, placental samples (50 
mg) were ground using a mortar and pestle with liquid nitrogen and mixed with 0.15 mL 
saline (0.9% w/v NaCl) as previously reported (117).  Homogenized samples were 
quickly frozen in liquid nitrogen and kept in -70°C until analysis. The samples were 
quickly thawed at 37°C and diluted 5 times in saline to 0.75 mL.  Twenty microliters of 
the diluted samples were incubated with 20 µL 1% deoxycholate at 37°C for 5 min, and 
10 µL of the samples were used to analyze either TG or NEFA.  TG content was 
analyzed via the Thermo Infinity Triglycerides Liquid Stable Reagent (Thermo Fisher 
Scientific) following company protocol and using a commercially available standard 
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reference kit (Verichem Laboratories). Placental NEFA concentration was determined 
using a commercially available kit (HR-2 Series, Wako Diagnostics).  The Lowry assay 
was performed to determine the protein concentration of each sample, which was then 
used to normalize the TG and NEFA concentrations.   
Because lipid accumulation has been shown to be accompanied by an increase in 
oxidative stress, the TBARS assay (Catalog # 10009055, Cayman Chemical, Ann Arbor, 
MI) was performed per company protocol to determine the concentration of MDA, a 
product of lipid peroxidation, within placental tissues.  Lowry assay was performed to 
normalize the data; however protein content did not differ between treatment groups, 
therefore raw data from this experiment are presented. 
 
Placental Oil Red O Staining 
Because OP placentas had increased accumulation of TG and NEFA when 
compared to OR, the localization of the lipid within the tissues was characterized.  In 
order to do this, frozen placentas from 5 dams (2 from each dam, for n=10) in each strain 
group were embedded in Tissue-Tek OCT compound (VWR, Radnor, PA) on dry-ice and 
2 sections were cut from each sample at a thickness of 7 µm and mounted on glass slides.  
Slides were then briefly washed in water, 60% Isopropanol and stained for 10 min in a 
60% working Oil Red O solution (Catalog #1277, Newcomer Supply, Middleton, NJ).  
Slides were then washed well in water and 60% Isopropanol, counterstained for 20 sec in 
hematoxylin, washed again in running water and coverslipped using an aqueous 
mounting media.  Images were obtained using a NanoZoomer Slide Scanner and NDP 
View software (Hamamatsu, Bridgewater, NJ). 
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Placental RNA Isolation and RT-PCR Analysis  
Because OP placentas had visible lipid accumulation within all regions, the 
mRNA expression of lipogenic genes was also analyzed in these placentas.  Additionally, 
because it was hypothesized that Dkk1 may be affected in placentas of obese animals, 
frozen placentas from 5 dams (2 from each dam, for n=10) from each strain were 
randomly chosen for mRNA analysis and matched to the placentas used for NEFA, TG, 
and TBARS analyses.  Total RNA was isolated using the GenElute™ Mammalian Total 
RNA Miniprep Kit (Sigma-Aldrich) and quantified using Nano Drop Spectophotometer 
ND-1000.  Two micrograms of cDNA was synthesized in a 20 µl reaction volume using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using random 
primers and a thermal cycler (Applied Biosystems 2700), with the following program: 
25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 seconds, and a 4°C hold.  Real-
time PCR was performed using 25 ng cDNA as the template, SYBR Green PCR Master 
Mix (Applied Biosystems), and 5 µmol/L of each forward and reverse primer (Table 7.2) 
in the 7300 Real-Time PCR System (Applied Biosystem), with the following program: 
95°C for 10 minutes, 95°C for 15 seconds, 60°C for 1 minute, 95°C for 15 seconds, 55°C 
for 1 minute, 95°C for 15 seconds, with 40 cycles of steps 2 and 3.  Primers were 
designed using the Vector NTI software (Invitrogen) and the Ensembl database and 
obtained from IDT (Integrated DNA Technologies, Coralville, IA).  Selection criteria for 
primers included the following: primer length of 18-25, a product length of 60-80 base 
pairs, a product that spans an exon and intron (whenever possible), few or no hairpin 
loops, and a melting temperature difference of < 0.3°C.  For each reaction, a serial 
dilution was created from a sample that originated from each study, and was used to 
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create a standard curve for quantification and a dissociation curve was analyzed 
following each reaction.  The reaction was deemed appropriate if the standard curve had 
a slope of  -3.3±0.2 and R2 > 0.98.  Appendix B shows the dissociation/melting curves 
for all primers utilized in the current study.  All mRNA data are expressed as a value 
following normalization to the L7a gene, the mean of which did not differ between 
treatment groups. 
 
Placental Immunofluorescence 
Because Dkk1 mRNA was significantly decreased in OP placentas, its protein 
content was also determined, as was the protein content of β-Catenin, the indicator of 
aberrant Wnt-signaling.  Frozen placentas (1 from each dam for n=5) in each strain group 
were embedded in Tissue-Tek OCT compound (VWR) on dry-ice and 2 sections were cut 
from each sample at a thickness of 10 µm and mounted on glass slides.  Samples were 
allowed to air dry and then fixed in ice-cold acetone for 10 minutes, followed by 10 
minutes of washing in PBS.  Samples were then blocked in Image-iT FX (Catalog # 
I36933, Invitrogen, Carlsbad, CA) for 45 minutes, washed 3 X 5 minutes with PBS, 
incubated in primary antibody for 1.5 hrs (1:150 for β-Catenin, Santa Cruz Catalog # sc-
1496 and 1:50 for Dkk1, AbCam Catalog # ab61034), counterstained with Alexa Fluor 
647(Catalog #A-21245, Invitrogen) secondary antibody at a 1:200 dilution for 1 hr at 
room temperature, washed 3 X 5 minutes with PBS.  Nuclei were stained with Hoechst 
(Catalog #33342, Invitrogen) for 15 minutes, followed by washing 2 X 5 minutes with 
PBS.  Slides were then coverslipped using ProLong Gold (Catalog# P36934, Invitrogen) 
and stored at room temperature overnight and viewed using the Zeiss Axiovert 200M 
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with the Apotome Structured Illumination Optical Sectioning System (Thornwood, NY).  
Results were determined by a blinded analysis of at least 6 areas within each sample. 
 
Hepatic Lipid Analysis and Oil Red O Staining in Neonatal Offspring 
The effect of maternal obesity on liver lipid accumulation in offspring was 
analyzed, and the procedure for this analysis was identical to that utilized for the 
placental study. 
 
Hepatic RNA Isolation and RT-PCR Analysis in Neonatal Offspring  
In order to determine whether lipid accumulation in livers of OP offspring was 
also associated with a decrease in Dkk1 (as seen in placenta), the mRNA expression of 
this gene was determined, and the procedure for this analysis was identical to that utilized 
for the placental study. 
 
Hepatic Chromatin Immunoprecipitation (ChIP) Analysis of the Dkk1 Gene in Neonatal 
Offspring 
In order to determine whether there are any epigenetic modifications occurring 
within the hepatic Dkk1 gene that lead to its decreased transcription in livers of OP 
offspring, ChIP analysis of histone modifications was performed using a modified 
protocol (118).  Livers from 10 offspring (5 male and 5 female) from each strain group 
were randomly chosen for sampling to assure that offspring from all dams were 
represented in the analysis.  Briefly, 200 mg of frozen liver samples were ground using a 
mortar and pestle with liquid nitrogen and washed with PBS.  The samples were 
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resuspended in PBS and cross-linked in 1% formaldehyde.  The chromatin was sonicated 
(Fisher Scientific model 100 Sonic Dismembrator) on ice with 6 bursts for 40 s at power 
setting 5 with 2 min cooling intervals between each burst.  Sheared chromatin was diluted 
in ChIP Dilution Buffer and incubated overnight on a hematology mixer (Model 346, 
Fisher Scientific) with 2 µg of each primary rabbit antibody at 4°C (H3Ac: Millipore 
catalog # 06-599, H4Ac: Upstate catalog # 06-866, H3K4Me2: Millipore catalog # 07-
030, H3K9Me3: Upstate catalog # 07-442, H3K27Me3: Upstate catalog # 07-449).  Pre-
blocked salmon sperm DNA/protein G agarose beads (60 µL, 50% slurry; Upstate 
Biotechnology, Lake Placid, NY) were then added to the chromatin samples, followed by 
2 hrs of incubation at 4°C.  Supernatant of normal rabbit IgG (Santa Cruz catalog # sc-
2027) was saved as input control.  Pellets containing the immunoprecipitated complexes 
were washed andd eluted from Protein G beads by adding elution buffer.  The 
supernatants were incubated at 65°C for 5 hr to reverse the formaldehyde cross-linking 
and release the DNA fragments.  Samples were then treated with proteinase K (Sigma-
Aldrich) at 37°C for 1 hr to remove any protein.  DNA was purified with a DNA 
miniprep system (Qiagen).  5µL of immunoprecipitated DNA was used for the real-time 
PCR reaction to analyze different genomic regions on the Dkk1 gene.  The Real Time 
PCR primers for the promoter covered the region that was between 143 base pairs (-143 
Forward, CCCAGCTTCCGATACACAAACACT) and 76 base pairs (-76 Reverse, 
AGCAGGGATGGGATTTCAAAGC) upstream of the transcription start site. 
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Cell Culture Studies 
Cell Culture and Treatment 
To determine whether the decreased Dkk1 expression was associated with 
elevated plasma NEFA observed in our model of gestational obesity, human JEG3 
trophoblast cells were obtained from ATCC (Manassas, VA, USA).  Minimum essential 
medium (MEM) was purchased from SCS Cell Media Facility at the University of 
Illinois at Urbana-Champaign (Urbana, IL, USA).  Fetal bovine serum (FBS) and other 
cell culture media supplements were purchased from Mediatech (Herndon, VA, USA).  
Cells were maintained at 37°C in a 5% CO2/95% air incubator, and were cultured and 
maintained in MEM media containing 10% (v/v) FBS, 100 IU/ml penicillin, 100 µg/ml 
streptomycin, and 250 ng/ml amphotericin B (Sigma-Aldrich).   
Passage 3 cells were seeded in a 6-well plate at 0.2 million cells per well on top of 
22X22 mm cover slips for Oil Red O staining and immunofluorescence, at 8 million cells 
per dish in 100 mm dishes for TBARS assay, at 1 million cells per dish in 60 mm dishes 
for RNA isolation in triplicate, and at 0.05 million cells per well in 24-well plates for Oil 
Red O quantification.  For the initial experiment using wild-type cells, cells were treated 
with either 0 or 400 µmol/L of Fatty Acid Supplement containing 2 moles of linoleic and 
1 mole oleic acid per mole of Bovine Serum Albumin (BSA) (Catalog #F7175, Sigma-
Aldrich) in triplicate.  This particular mixture of free fatty acids was selected because it 
has been suggested that the placenta has a preferential uptake of the fatty acids (and other 
PUFAs).  Please see the Discussion section for further details.  The 400 µmol/L 
concentration was chosen because a concentration gradient using 0, 25, 50, 100, 200, and 
400 µmol/L NEFA showed that DKK1 was significantly decreased following the 25, 50, 
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100, and 200 µmol/L NEFA treatment when compared to the 0 µmol/L treatment, but 
was maximally decreased following the 400 µmol/L NEFA treatment (data not shown).  
Additionally, 400 µmol/L has been shown to be a physiologically attainable NEFA 
content in the plasma of pregnant women, and corresponds to a level of plasma NEFA 
that is between OR and OP rats in the current study.  Treatment media made for the 0 
µmol/L treatments was supplemented with additional BSA to mimic the 400 µmol/L 
treatment.     
 As discussed below, cells were incubated with NEFA for a total of 24 hours.  
Initial time course experiments showed that by 12 hours, the expression of DKK1 was 
not consistent among the triplicates, and that the 24 and 48 hour treatments showed a 
similar pattern of expression (data not shown).  Because the overexpression protocol 
requires that the transfection not exceed 72 hours, we chose the 24 hour NEFA treatment 
for the current experiment (24 hours of NEFA treatment+48 hours of transfection). 
 
Overexpression of Dkk1 in JEG3 Cells  
Because Dkk1 mRNA was downregulated and fat accumulation increased in 
NEFA-treated JEG3 cells, the ability of Dkk1 overexpression to prevent the accumulation 
fat in these cells following NEFA treatment was also determined.  Transfection-ready 
Dickkopf homolog 1 (Dkk1) DNA inserted into a pCMV6-XL5 vector was purchased 
from OriGene (Catalog #SC303946, mRNA NCBI Reference Sequence NM_012242.2, 
Rockville, MD).  The empty pCMV vector was isolated and used as a transfection 
control.  JEG3 Cells were grown as described above and transfected with either the 
Dkk1-containing vector or the empty pCMV.  The transfection mixture was prepared 
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with each vector (1.5 µg per well for 6-well plates and 0.5 µg per well for 24-well plates), 
serum-free media and Superfect Transfection Reagent (Catalog #301307, Qiagen, 
Valencia, CA).  After being transfected with the resulting mixture for 3 hours at 37°C in 
a 5% CO2/95% air incubator, cells were replenished with fresh complete MEM 
(containing 10% (v/v) FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 250 ng/ml 
amphotericin B) for 48 hours to allow for the expression of both Dkk1 mRNA and 
protein.  Cells were then treated with either 0 or 400 µmol/L of Fatty Acid Supplement 
containing 2 moles of linoleic and 1 mole oleic acid per mole of BSA.    
 
Analysis of Wnt Components and Fat Accumulation in Normal and Dkk1-Overexpressed 
JEG3 Cells Following NEFA Treatment 
After 24 hours of NEFA treatment, cells were collected into Tri Reagent (Catalog 
# T9424, Sigma-Aldrich) to isolate RNA per manufacturer’s protocol.  Methodology for 
RNA quantification and mRNA analysis in JEG3 cells is identical to that described for 
placental tissues.     
After 24 hours of NEFA treatment, cells were fixed in 4% Paraformaldehyde 
(Catalog #P6148, Sigma-Aldrich) in PBS for 1.5 hours for Oil Red O staining.  Each well 
was then washed with PBS, and the same protocol was followed as for tissue Oil Red O 
staining.  Following staining, coverslips containing the stained cells were mounted on 
glass slides and visualized as with tissue samples.  For quantification of the Oil Red O 
staining, cells grown in 24-well plates were also fixed in 4% Paraformaldehyde as 
discussed above, and then were washed 3 times with water, stained with Oil Red O stain 
for 20 minutes and washed 3 times very well with water.  The dye was extruded with 
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100% Isopropanol for 10 minutes, and the resulting supernatant was transferred to 96-
well plates and analyzed specrophotometrically at an OD of 490 nm.   
For the initial experiment in JEG3 cells, data were presented using a modified y-
axis to account for the background from the visible oil red O stain still remaining on the 
walls of all wells.  For the transfection experiment, data were presented as the % of 
change between the pCMV and Dkk1-transfected cells following 400 µmol/L of NEFA 
treatment.  The lack of a transfection effect on cell number was confirmed by performing 
Lowry Protein analysis on adjacent cells exposed to the identical treatment.   
The protocol for immunofluorescence staining of β-Catenin protein in JEG3 
cells was similar to that used for tissue samples, except that cells grown on coverslips  
were first mounted on glass slides before proceeding with the staining protocol.  
TBARS assay (Catalog # 10009055, Cayman Chemical) was performed per 
company protocol to determine the concentration of MDA, a product of lipid 
peroxidation, within JEG3 cells following NEFA treatment.. Lowry assay was performed 
to normalize the data; however protein content did not differ between treatment groups, 
therefore raw data from this experiment are presented. 
 
Analysis of Dkk1 mRNA Expression and Fat Accumulation in H4IIEC3 Cells Following 
NEFA Treatment 
In order to determine the potential effect of elevated circulating or hepatic lipids 
on Dkk1 mRNA content and lipid accumulation, rat H4IIEC3 hepatocyte cells were 
obtained from ATCC (Manassas, VA, USA) and incubated with NEFA.  All lipid 
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accumulation and mRNA analyses were identical to that used for the JEG3 study, except 
that H4IIEC3 cells were analyzed following 48 hours of NEFA treatment. 
 
Statistical Analysis 
Results are reported as means ± SEM.  The n=5 for maternal food intake, weight 
gain, and plasma analysis.  Fetal and placental weight analysis was performed by taking 
the average of weights by litter, with a resulting n=5.  The fetal:placental ratio was 
obtained for every individual offspring and placenta, and the average was taken for all 
litters, with a resulting n=5.  For placental and hepatic mRNA analysis, ChIP analysis, 
Oil Red O staining, TBARS, lipid content, and placental thickness measurements, n=10.  
For determination of decidual/junctional thickness, 5-7 measurements were taken per 
placenta using NDP View software (Hamamatsu, Bridgewater, NJ) from samples 
previously stained and scanned for Oil Red O content.  For placental 
immunofluorescence, n=5.  All cell culture experiments we run in triplicate.   
Maternal weight and food intake were analyzed using the repeated measures 
ANOVA (SAS software, Cary, NC).  For all remaining data, Student’s t-test was used to 
test differences between means, and means were considered significantly different when 
P<0.05. 
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CHAPTER 4: RESULTS 
 
Animal Study: Maternal and Placental Data 
Maternal Gestational Characteristics 
Gestational food intake (Figure 8.1) was not different between OR and OP dams 
throughout gestation, however, OP dams were significantly heavier (P<0.01) than OR 
throughout gestation (Figure 8.2), and the ratio of food intake per gram of body weight 
was significantly lower (P<0.05) in OP dams when compared to OR (Figure 8.3).  Total 
gestational weight gain was not different between OR and OP dams, and neither was 
mass gain (calculated by subtracting fetal and placental weights from total gestational 
weight gain) (Table 7.3).  At the time of cesarean delivery on gestational d 21, OP dams 
had significantly higher (P<0.01) levels of fasting plasma TG (Figure 8.4) as well as 
serum NEFA (Figure 8.5) (P<0.01).   
 
Offspring Observations And Placental Lipid Analysis  
At the time of Cesarean delivery on gestational day 21, offspring of OP dams 
were significantly lighter (P<0.01), when compared to offspring of OR dams (Table 7.3), 
the size of OP litters was significantly larger (P<0.05) than that of OR (Table 7.3), but 
the products of conception did not differ between the two groups (Table 7.3).  Placental 
weight was not different between the two strains, but the fetal:placental weight ratio was 
significantly lower in OP dams when compared to OR (Table 7.3).  OP dams had 
significantly (P<0.05) higher placental TG (Figure 8.6) and NEFA (Figure 8.7) content 
when compared to OR placentas.  Oil Red O staining of OR and OP placentas suggested 
 
 
38 
that OP placentas had visibly more lipid associated with the labyrinthine, decidual and 
junctional zones, while OR placentas had little lipid accumulation within all zones 
(Figure 8.8). Additionally, the combined thickness of the decidual and junctional zones 
was significantly narrower (P<0.01) in OP placentas when compared to OR (Figure 8.9).   
The mRNA content of fatty transporters Fatp1 and Fat/Cd36 were significantly 
higher (P<0.01) in OP dams, as was the mRNA content of genes associated with TG 
synthesis, including Ppar-delta, Dgat, Lipin1, and Lipin3, without a significant change in 
Lipin2 (Figure 8.10).  Despite the increase in lipid content within the OP placentas, there 
was no significant difference in the MDA concentration between OR and OP placentas 
(Figure 8.11).   
 
Placental Dkk1 And β-Catenin Content 
Dkk1 mRNA content was significantly (P<0.01) lower (>4 fold) in OP placentas 
when compared to OR (Figure 8.12), as was the amount of Dkk1 protein within the 
decidial/junctional and labyrinthine zones (Figure 8.13).  OP placentas also had a visible 
increase of β-Catenin protein within all regions when compared to OR (Figure 8.14).  
 
Cell Culture Study: Trophoblast Analysis 
Fat Accumulation And Dkk1 mRNA Content in NEFA-treated JEG3 Cells 
Treating JEG3 cells with 400 µmol/L of NEFA resulted in a significant decrease 
(P<0.01) in the content of DKK1 mRNA when compared to the 0 µmol/L treatment 
(Figure 8.15).  Additionally there was obvious fat accumulation in cells treated with 400 
µmol/L of NEFA when compared to the 0 µmol/L treatment as observed by Oil Red O 
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staining (Figure 8.16) and quantified by extruding the Oil Red O dye (P<0.01) (Figure 
8.16), without a significant difference in the MDA concentration between the two 
treatments (Figure 8.17). 
 
Fat Accumulation and Wnt Signaling in NEFA-treated JEG3 Cells Overexpressing DKK1 
The overexpression of DKK1 was confirmed by testing mRNA content of the 
DKK1 gene following transfection and NEFA treatment (Figure 8.18).  Additionally, the 
overexpression of DKK1 (+Dkk1) and NEFA treatment resulted in a decrease of β-
Catenin protein when compared to the WT (wild-type) transfection (Figure 8.19).  
Although we did not observe any obvious differences in the number of lipid droplets 
between WT-transfected and +Dkk1 cells, there did appear to be fewer bright red droplets 
and more pink drops in the +Dkk1 samples (Figure 8.20 top).  Additionally, 
quantification of the Oil Red O staining showed that there was a significant (P<0.01) 
decrease of 10% in fat accumulation in +Dkk1 cells following NEFA treatment when 
compared to WT-transfected cells (Figure 8.20 bottom).   
When compared to WT-transfected cells, +Dkk1 cells also had a significant 
decrease in the mRNA content of PPAR-Delta (P<0.01), FATP (P<0.05), DGAT 
(P<0.01), LIPIN2 (P<0.05), and LIPIN3 (P<0.05) without a significant change in 
FAT/CD36 and only a trend of decrease of LIPIN1 (P=0.059) (Figure 8.21).  
 
Animal Study: Liver Analysis in Neonatal Offspring 
Hepatic Lipid Content and Accumulation and Dkk1mRNA Expression in Neonatal 
Offspring 
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OP offspring had significantly higher (P<0.05) liver TG content when compared 
to OR (Figure 8.22 ), while there was no significant difference in hepatic NEFA content 
between OR and OP offspring (Figure 8.23).  Oil Red O staining in livers of OR and OP 
offspring suggested that OP neonatal livers had visibly more lipid content than livers of 
OR neonates (Figure 8.24).  Dkk1 mRNA content was significantly lower (P<0.05) in 
livers of OP offspring when compared to OR (Figure 8.25).   
 
Hepatic Histone Modifications by ChIP Analysis of the Dkk1 Gene in Neonatal Offspring 
Promoter analysis of the hepatic Dkk1 gene demonstrated that maternal obesity 
led to a significant decrease (P<0.05) in the amount of H3Ac, H4Ac, as well as 
H3K4Me2 associated with the Dkk1 promoter in livers of OP offspring when compared 
to OR (Figure 8.26).  However, there was no difference in the amount of either 
H3K9Me3 or H3K27Me3 associated with the hepatic Dkk1 promoter between OR and 
OP offspring (Figure 8.26).  There was also no effect by maternal obesity in the amount 
of IgG binding within the region tested, which was used as a control (Figure 8.26). 
 
Cell Culture Study: Hepatocyte Analysis 
Lipid Accumulation and Dkk1 Expression in NEFA-Treated H4IIEC3 Cells 
At the highest NEFA concentration of 400 µmol/L, there was a significant 
decrease (P<0.05) of Dkk1 mRNA content (Figure 8.27).  There was also an increase in 
lipid accumulation with increasing NEFA concentration (Figure 8.28 bottom), with no 
observable red droplets in the 0 µmol/L NEFA-treated group and many visibly red 
droplets in the 400 µmol/L NEFA-treated cells (Figure 8.28 top).
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CHAPTER 5: DISCUSSION 
 
To our knowledge, the present study is the first to present evidence that placental 
lipid storage and metabolism may be regulated in part through the placental Wnt 
pathway.  These novel findings demonstrate that Wnt signaling may be directly involved 
in the accumulation of fat within the placenta, a pathophysiology that may have dire 
consequences for placental efficiency and fetal development. 
Although data related to the current obesity prevalence in pregnancy is limited, 
several cohort studies predict that the figures match the increase in obesity in the 
population as a whole (28).  Current recommendations for pregnant women focus 
primarily on controlling weight gain during pregnancy.  However, there is increased 
evidence that pre-pregnancy weight may be as important to gestational and fetal health as 
the total amount of weight gained.  Overall, studies have shown that maternal obesity, 
which has been associated with central subcutaneous adiposity, correlates strongly to 
gestational diabetes, hypertension and pre-eclampsia (30-34).   
The current study utilized an obesity-prone rat model, which allowed us to 
observe the consequence of excessive body weight on the placenta without the potentially 
confounding effect of high-fat intake often observed in other models of diet-induced 
obesity.  This approach is a unique and critical feature of the current study, as women are 
more likely to follow appropriate dietary recommendations during pregnancy than they 
may be before or after becoming pregnant. Therefore, a HF-diet-induced model of 
obesity was not appropriate for to accomplish our study aims.  The current model of 
obesity has been well-characterized and is thought to exhibit many of the characteristics 
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of humans who are obese and have other symptoms of metabolic syndrome.  Appendix 
A contains a thorough review of studies utilizing the model of Diet-Induced Obesity 
(DIO) as well as Obesity Proneness (OP) and Obesity Resistance (OR).  
Fasting triglycerides were higher in OP than in OR dams, suggesting that the 
obese animals have a decreased ability to clear triglycerides, even after an overnight fast.  
This observation has been shown to be characteristic of the current model during the non-
pregnant state, and has been likened to severely obese individuals who also have a 
disregulation in TG metabolism (11).  In our study, OP dams had significantly higher 
NEFA levels than OR, and that OP dams also gave birth to growth-restricted offspring.  
Elevated NEFA levels are often seen in obese individuals (119), and it has been observed 
that pregnancies complicated with IUGR are also associated with elevated NEFA (120, 
121), which agrees with our results. 
We observed a significant decrease in birth weights of offspring from OP dams 
when compared to OR.  Low birth weight, or IUGR, is associated with increased risk of 
numerous adult-onset diseases (122).  Maternal obesity has most often been associated 
with fetal overgrowth, but there is evidence that obesity can also result in small-for-
gestational-age offspring (41-44).  It was previously believed that conditions that lead to 
decreased placental size (and therefore decreased area for nutrient transport and waste 
export) lead to IUGR (2, 3, 59).  However, recent reports suggest that the ratio of fetal-to-
placental weight is a better marker of placental efficiency, as it represents the amount of 
fetus produced for each gram of placenta.  The ratio has been evaluated by several 
studies, which have concluded that a large placenta, when accompanied by a smaller 
fetus, is associated with IUGR as well as SGA offspring, gestational diabetes, and 
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possible risks of late-onset diseases (4-6, 59).  In this study, we found that placental 
weight was not affected by maternal weight, but that the fetal:placental ratio was 
decreased in obese dams, indicating that despite being the same size as those of lean 
dams, the placentas of these dams were not able to support proper fetal development.  
Additionally, in the current study, placentas of OP dams had a significant decrease in the 
thickness of the decidual and junctional zones, with a concurrent increase in lipid 
accumulation.  Appropriate vascularization and angiogenesis within the decidual zone is 
imperative for placental and fetal development (123), and any disruptions within its 
development could be potentially detrimental.  We observed extensive decidual lipid 
accumulation, and although there is little data available regarding the consequence of this 
observation on the placenta, studies in other organ systems have shown that excessive fat 
accumulation results in substantial damage to cellular components and tissue structure 
(124).  
Offspring born small for gestational (SGA) age are at risk for developing 
metabolic syndrome in adulthood (122), and it has recently been reported that SGA 
children may also be at risk for NAFLD (125). This is consistent with our results, since 
although OP offspring were smaller at birth, they had higher hepatic TG than OR and 
appeared to have an increase in lipid accumulation as measured by Oil Red O staining 
than OR, indicating their tendency to store lipid within the liver instead of utilizing the 
available energy substrates for growth.  While no other studies have looked at the effects 
of obesity on pregnancy outcomes in the current model, a study of OR and OP mice 
showed that although OP dams gave birth to smaller pups, after being weaned to a 
standard diet for 13 weeks, offspring of OP dams were significantly heavier than 
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offspring of OR dams (126).  Although we did not keep our pups past neonatal d 1, this 
observation is likely to also be true for animals in the current study, and likely accounts 
for reports that IUGR offspring tend to weigh more in adulthood than those babies born 
normal for gestational size.     
Canonical Wnt signaling is activated by the binding of a Wnt molecule, which 
allows β-Catenin to accumulate in the nucleus and act as a transcription factor (85, 86, 
127).  Dkk1, a secreted-type inhibitor, interacts with and cause the endocytosis of 
LRP5/LRP6 coreceptor to prevent the formation of the Wnt-FZD-LRP5/LRP6 complex.  
In a pregnant mouse model, Dkk1 was highly expressed in the maternal decidual 
compartment, and culturing decidual cells in the presence of antisense Dkk1 decreased 
trophoblast invasiveness, while treatment with antisense β-Catenin increased trophoblast 
attachment and invasiveness, suggesting that an increase in Wnt signaling may prevent 
decidualization and trophoblast cell invasion (128).  The inhibitory role of Wnt signaling 
on vascularization, in association with decreased Dkk1, has been shown in cases of 
diabetic retinopathy (129), in human umbilical vein endothelial cells (130), as well as in 
human breast tumors (131).  In the current study, Dkk1 was significantly decreased and 
β-Catenin significantly increased in OP placentas, which corresponds to an inappropriate 
activation of Wnt signaling in “fatty” placentas that had a significant decrease in 
decidual/junctional thickness.  Dkk1 mRNA expression was also decreased in trophoblast 
cells treated with NEFA, and the accumulation of fat was decreased when Dkk1 was 
overexpressed in these cells followed by NEFA treatment, suggesting that fat 
accumulation within trophoblasts is regulated in part by Wnt signaling.   
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The mRNA content of Ppar-delta was significantly increased in placentas of OP 
dams, and significantly decreased when JEG3 cells that overexpress DKK1 were treated 
with NEFA.  Because PPAR-Delta has been shown to contain a β-Catenin responsive 
element within its promoter (132), we propose that the aberrant activation of Wnt 
signaling in OP placentas results in the activation of Ppar-delta, which was been shown 
to be a potent inducer of adipogenesis and lipogenesis (133).  Although all three PPAR 
isoforms have been shown to be expressed in the placenta (134), their exact actions have 
not been thoroughly classified.  
In the current study, we utilized the JEG3 trophoblast cell line in order to study 
the relationship between fat accumulation and the Wnt signaling pathway.  JEG3 
choriocarcinoma cells originated from a line of human extravillous trophoblasts, which 
makes them an ideal model for studying invasion, vascularization, and the transport of 
molecules that occurs at the primary interface between maternal and fetal tissues (135).  
Extravillous trophoblasts function as anchors connecting maternal and fetal interfaces, 
which is the reason for the frequent use of JEG3 cells in placental functional studies 
(136-138).  The cell line has also been utilized in numerous studies to model 
syncytiotrophoblasts, or the direct layer of villous chorionic villi exposed to the maternal 
blood supply (139).  
Additionally, we treated cells with a NEFA mixture composed of oleic and 
linoleic acids, an approach similar to that which has been utilized by previous studies of 
trophoblast fat accumulation (140-142). Additionally, studies have shown that the 
placenta may have a preference for transporting these acids (as well as DHA), 
presumably to guarantee an ample supply of these essential fatty acids to the fetus (143, 
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144). It has also been suggested that because glucose is the primary energy source for the 
fetus, the polyunsaturated fatty acids in particular function to provide the fetus with 
structural and metabolic components and do not serve as energy substrates (145). 
The rates of childhood non-alcoholic fatty liver disease are increasing, and 
children with NAFLD are at risk for end-stage liver disease as well as insulin resistance 
and other symptoms of metabolic syndrome in adulthood (68, 146).  The present study is 
the first to demonstrate that gestational obesity programs lipid accumulation in fetal liver 
with a concurrent decrease in the hepatic mRNA content of a potent inhibitor of Wnt, 
Dkk1, through histone modifications.  We further showed that NEFA alone might lead to 
a decrease of Dkk1 mRNA content in vitro.  The role of Dkk1 in hepatic lipid metabolism 
is poorly understood.  Although Dkk1 expression is elevated during hepatocellular 
carcinoma, its function in cancer and hepatic lipid accumulation is likely to be different, 
as Dkk1 has been shown to be both upstream as well as downstream of β-Catenin (79), so 
the full Wnt pathway will need to be evaluated to fully characterize Dkk1’s mechanism of 
action. 
Although the role of Dkk1 in NAFLD remains unclear, it is certain that Wnt plays 
an important role in liver development as well as lipid metabolism, as shown by our 
placenta study.  Therefore, it is notable that out ChIP analysis of the Dkk1 promoter in 
neonatal livers demonstrated that the gene is regulated epigenetically in response to 
maternal obesity.  The modification of histone tails through H3Ac, H4Ac, as well as 
H3K4Me2 are all known to be increased in actively transcribed genes (147-149), and we 
propose that the decreased expression of Dkk1 in livers of OP offspring is directly related 
to the decrease in these histone marks.  If these marks persist into adulthood, this histone 
 
 
47 
code will likely result in the perpetual decrease in Dkk1’s transcription, which will 
potentially lead to the uncontrolled activity of Wnt signaling, the consequence of which 
may be detrimental.    
In conclusion, this study demonstrates, for the first time, a coordinated regulation 
of placental lipid metabolism by a β-Catenin inhibitor, Dkk1.  While both the placenta 
and fetus require an extensive supply of essential fatty acids during gestation, we show 
that an excessive availability of NEFA in circulation leads to placental fat accumulation, 
potentially in response to aberrant Wnt activation.  As the primary mode of 
communication between mother and fetus, the placenta plays an integral part in the 
adaptations that occur in a nutrient-restricted or abundant pregnancy, and any 
disregulations within placental structure may be deleterious for both placental and fetal 
development.  Additionally, we showed that maternal obesity was associated with lipid 
accumulation in livers of neonatal offspring, which is a classic marker of NAFLD, and 
that Dkk1 in these livers was epigenetically regulated.  We propose that determining the 
mechanisms behind the in utero development of the disease may help decrease the rates 
of childhood NAFLD and prevent its progression into adulthood. 
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CHAPTER 6: FUTURE DIRECTIONS 
 
Alternate Models of Gestational Obesity 
Although the OP rats should become obese on a HF diet, our OP rats maintained 
their obesity status despite being on a control diet throughout gestation.  This 
phenomenon has been observed in previous studies of obesity-prone rats (150), and 
allowed us to effectively demonstrate the consequences of being obese during pregnancy 
without the confounding effect of diet.  As demonstrated in Appendix A, diet-induced, as 
well as obesity models developed by selective breeding in rats are commonly utilized 
approaches towards modeling metabolic syndrome in the human population.  However, 
fewer studies have focused on the consequences of being obese during pregnancy, so it 
still remains unclear which models are most advantageous for this analysis.  Feeding OP 
rats a Control and HF diet would add valuable information on this strain, and would 
potentially model human cases in which obese women did or did not follow dietary 
recommendations during pregnancy.  Because obesity is often familial as well as 
lifestyle-induced, we consider that our strain of breeding-induced obesity is optimal for 
the current analysis.  However, an additional approach would be to utilize standard 
Sprague-Dawley rats fed a HF diet for an extended period of time in order to obtain a true 
diet-induced model of obesity.  Although this would eliminate any breeding-induced 
obesity characteristics, it would also introduce diet as a confounding factor.  
Additionally, Sprague-Dawley rats are notoriously inconsistent in their weight gain 
response to high-fat or high-energy feeding, making them similar to humans, so it is 
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probable that the animal number for such a study would be fairly large and would depend 
on whether the animals could gain enough weight on the diet.     
 
Analysis of Placental Size and Dimensions as an Additional Indicator of Placental 
Efficiency   
In the current study, placental weight remained unchanged while lipid 
accumulation increased in OP placentas when compared to OR.  Because lipid likely 
weighs less than other placental components, it is probable that while placental weights 
did not change, there was a difference in placental size and dimension between OR and 
OP placentas, and these factors were not measured in the current study.  Although studies 
are limited, it has been suggested that placental surface area and other dimensions, and 
not weight per-se, may be associated with poor fetal outcomes (151-153), so performing 
such an analysis in any future studies of obesity during pregnancy may be a valuable 
marker of fetal as well as placental development. 
 
Placental Primary Cultures with NEFA Incubation, or Incubation of JEG3 Cells With 
Sera From Obese Versus Lean Women 
 Primary cultures of specialized cells are difficult to obtain and maintain, so JEG3 
was selected for the current analysis because it originated from a line of cells vital for 
placental structure and transport.  Our cell culture analysis showed a direct relationship 
between NEFA, Wnt, and placental lipid accumulation.  However, the JEG3 cell line 
represents just one of several placental cell-types, so a primary culture of a variety of 
human placental cell-types would be an additional approach to further study the 
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consequences of being obese during pregnancy on placental molecular pathways.  
Additionally, while we isolated the effect of elevated NEFA in obese women on Wnt 
signaling, other plasma factors differ between lean and obese women, so utilizing 
complete sera from women with varying degrees of obesity or other markers of metabolic 
syndrome would add important knowledge to the study of obesity during pregnancy and 
placental development.   
 
Alternate Measures of Oxidative Stress or Determination of the Mechanisms Behind 
Peroxidation Prevention 
 While numerous studies have shown that excess lipid accumulation leads to the 
oxidation of lipids, we did not observe an increase of MDA, a marker of lipid 
peroxidation, in OP placentas when compared to OR.  Although the TBARS assay is a 
valid and commonly utilized approach to measuring lipid-induced oxidation, it has been 
suggested to be somewhat unspecific and dependent on the content of specific fatty acids 
(154-156), so other approaches may be more appropriate.  Additionally, if our TBARS 
results are in fact correct, and there is no increase in lipid peroxidaton in OP placentas 
when compared to OR, it would be valuable to elucidate the molecular mechanisms 
behind this antioxidant defense system. 
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Binding Analysis within the Ppar-Delta PromoteraAs well as Within the Promoters of 
Target Genes to Determine the Precise Role of β-Catenin and the Mechanism Behind its 
Activation 
 We observed that the overexpression of DKK1 in NEFA-treated cells results in 
decreased lipid accumulation and expression of lipid metabolism-associated genes.  
Specifically, we observed that an increase in β-Catenin was also accompanied by a 
decrease in PPPAR-Delta, a potent activator of lipid metabolism.  We also observed that 
OP placentas had increased Ppar-Delta mRNA content and β-Catenin protein.  It has been 
suggested that PPAR-Delta is a downstream target of β-Catenin, but this needs to be 
confirmed in the current study in order to determine whether the decrease in lipid 
accumulation we observed was due to the decrease in PPAR-Delta-activated genes in 
response to β-Catenin inhibition.  ChIP analysis within the PPAR-Delta promoter, both 
within our cell culture model and in placental tissue samples, would add valuable 
information related to its control by β-Catenin.  Additionally, binding studies of PPAR-
Delta itself within the promoters of lipid transporters and TG synthesis-related genes 
would confirm the role of this transcription factor in placental lipid accumulation in 
response to gestational obesity.   
 
Role of Wnt in other Tissues that have Potential Ectopic Lipid Accumulation, Including 
Liver, Pancreas, and Muscle 
 We have demonstrated a potentially novel role of Dkk1 and Wnt signaling in 
placental lipid metabolism.  However, the role of Wnt in other tissues is not yet well-
characterized.  Studies have suggested that the inhibition of Wnt is necessary for the 
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maturation of pre-adipocytes in adipose tissues.  However, the additional accumulation of 
mature adipocytes is associated with increased levels of β-Catenin, suggesting that in 
adipose tissue, the role and action of Wnt fluctuates with adipogenesis progression (157).  
In liver, β-Catenin has been shown to be necessary for the prevention of lipid 
accumulation, since mice with liver-specific β-Catenin knockouts developed non-
alcoholic fatty liver disease in response to a steatogenic diet (158).  Therefore, it appears 
that Wnt may be a relatively novel and promising pathway for the study of adipogenesis, 
and particularly in metabolically-active tissues at risk for ectopic lipid accumulation in 
response to obesity, such as liver, pancreas, and muscle.  
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CHAPTER 7: TABLES 
 
Table 7.1:  Animal Diets.  Obesity-Resistant (OR) and Obesity-Prone (OP) dams were 
fed a control diet ad libitum beginning on gestational day 2 until they were fasted on 
gestational day 20. 
 
Diet Composition (Per 12.5 kg) 
  Control (C) 
  Gram %  kcal % 
Protein  20  20 
Carbohydrate  64  64 
Fat   7   16 
Total  91.0  100 
kcal/g  3.9   
Ingredients    Gram    kcal 
Casein  200  800 
L-Cystine  3  12 
Corn Starch  437.2  1749 
Maltodextrin  100  400 
Sucrose  102  408 
Cellulose  50  0 
Soybean Oil  25  225 
Lard  47  423 
Mineral Mix  10  0 
DiCalcium Phosphate  13  0 
Calcium Carbonate  5.5  0 
Potassium Citrate  16.5  0 
Vitamin Mix  10  40 
Choline Bitartrate   2   0 
Total  1021.25  4057 
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Table 7.2:  Primer Information.   
Gene Species Forward Sequence and Location   Reverse Sequence and Location   Ensembl ID 
Dkk1 Rat  ATGCCCTCTGACCACAGCCATT (+439)  CACCGTGGTCATTGCCAAGGT (+517)  ENSRNOT00000015771 
 Human  GATCATAGCACCTTGGATGGG (+635)  GGCACAGTCTGATGACCGG (+742)  ENST00000373970 
Ppar-Delta Rat  GCTCACCGAGTTCGCCAAGAAC (+1024)  CCTCATGCACGCCGTACTTGAG (+1112)  ENSRNOT00000042539 
 Human  CCCCACGTCTGTCCTCCTTTCTTAT (+1954)  TGTGCAAAAGCAGAGGTCCTGTTC (+2039)  ENST00000360694 
Fatp1 Rat  CCACCATTCCTACAGCAT (+996)  TGCTGAGTGGTAGAGAGGTA (+1062)  ENSRNOT00000024659 
 Human  AACCTCAGAGGAACCCGTGCCT (+2137)  TGAAAAGCAGGGAGAGGAGGC (+2206)  ENST00000252595 
Fat/CD36 Rat  AGTGCTCTCCCTTGATTCTGC (+151)  GAGCCCACAGTTCAGATCACA (+213)  ENSRNOT00000061687 
 Human  CAAGAAAAATGGGCTGTGACCG (+247)  AACACAGCCAGGACAGCACCAAT (+319)  ENST00000447544 
Dgat1 Rat  TCAATCTGTGGTGCCGCCAG (+708)  CCCACTGACCTTCTTCCCTGCA (+775)  ENSRNOT00000039795 
 Human  GTGGCTTCAGCAACTACCGT (+507)  CGGGCATTGCTCAAGATC (+573)  ENST00000332324 
Lipin1 Rat  AGCCTGGTAGATTGTCAGAG (+738)  GAGGACAAGAGCTAGAGAGAAC (+804)  ENSRNOT00000005863 
 Human  GCGTAAAATGTCCCAAGCAGCC (+2761)  CGGGGAGACCTATCCTTTAATGGG (+2836)  ENST00000256720 
Lipin2 Rat  CCAGTTACCCACAGACAGTGTGCC (+792)  CTCTCGGATGGCTTCACCTCCA (+855)  ENSRNOT00000020476 
 Human  ACCACCTATCCCCAGACAGCGT (+936)  CAGGCTCTCCGCAGGTTTCA (+1004)  ENST00000261596 
Lipin3 Rat  CCCTGAAGAGAAGCCAGCACCT (+1107)  TCAGAGTCCAGGGAGGGCAGAT (+1176)  ENSRNOT00000067531 
 Human  CGGCACCATCACCAAGTCAGAT (+2029)  TGGTGTGTCCAGTCTTTCCCCA (+2097)  ENST00000373257 
L7a Rat  GAGGCCAAAAAGGTGGTCAATCC (+64)  CCTGCCCAATGCCGAAGTTCT (+127)  ENSRNOT00000006754 
  Human   TTTGGCATTGGACAGGACATCC (+145)   AGCGGGGCCATTTCACAAAG (+208)   ENST00000323345 
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Table 7.3: Maternal and Fetal Observations.  Obesity-Resistant (OR) and Obesity-
Prone (OP) dams underwent cesarean delivery on gestational day 21.  n=5 litters. Results 
are reported as means ± SEM. *P<0.05 when compared to OR.  #P<0.01 when compared 
to OR. 
 
Maternal And Fetal Observations 
Variable  Strain 
  OR  OP 
Total Gestational Weight Gain (g)  124.20 ± 2.67  128.78 ± 6.36 
Total Mass Gain (g)  74.98 ± 4.74  78.63 ± 6.93 
Birth Weight (g)  4.14 ± 0.24  3.44 ± 0.08# 
Placental Weight (g)  0.50 ± 0.01  0.49 ± 0.01 
Fetal:Placental Ratio  8.26 ± 0.41  7.11 ± 0.16# 
Products of Conception (g)  49.22 ± 3.17  50.15 ± 1.26 
Litter Size   10.60 ± 0.68   12.80 ± 0.58* 
*P<0.05 When Compared to OR     
#P<0.001 When Compared to OR     
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CHAPTER 8: FIGURES 
 
Figure 8.1, 8.2, 8.3: Food Intake and Body Weight Information.  Gestational food intake (Figure 8.1), body weight (Figure 8.2) 
curves, and amount of food (g) per gram of body weight (Figure 8.3) in Obesity-Resistant (OR) and Obesity-Prone (OP) dams 
throughout pregnancy.  Results are reported as means ± SEM.  n=5 litters.  *P<0.01 when compared to OR. 
 
Figure 8.1              Figure 8.2             Figure 8.3 
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Figure 8.4, 8.5, 8.6, 8.7: Triglyceride and Non-Esterified Fatty Acid Measurements.  Fasting plasma Triglycerides (TAG) 
(Figure 8.4) and Non-Esterified Fatty Acids (NEFA) (Figure 8.5), as well as placental TG (Figure 8.6) and NEFA (Figure 
8.7) in Obesity-Resistant (OR) and Obesity-Prone (OP) dams at the time of cesarean delivery on gestational d21. Results are 
reported as means ± SEM.  n=5 litters.  *P <0.05 when compared to OR.  #P <0.01 when compared to OR. 
 
 
Figure 8.4        Figure 8.5 
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(Figure 8.4, 8.5, 8.6, 8.7 Continued)  
Figure 8.6        Figure 8.7 
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Figure 8.8, 8.9, 8.10, and 8.11: Placental Characteristics.  Representative image of Oil Red O Staining of placental fat 
accumulation in placentas of Obesity-Resistant (OR) (Figure 8.8 left) and Obesity-Prone (OP) (Figure 8.8 right) dams with 
magnified images for clearer viewing.  “Lz”: Labyrinthine Zone, “Jz”: Junctional Zone, “Dz”: Decidual Zone”.  Arrows point 
to areas of significant red staining.   Measurement of the decidual/junctional thickness (Figure 8.9), mRNA analysis (Figure 
8.10), and Malondialdehyde MDA concentration analysis (Figure 8.11) was performed in placentas of 5 dams (2 from each 
dam, for n=10) from each strain, with 5-7 measurements per placenta for thickness measurement.  Results are reported as 
means ± SEM.  *P<0.01 when compared to OR. 
 
Figure 8.8                Figure 8.9  
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Figure 8.8, 8.9, 8.10, and 8.11 (Continued) 
Figure 8.10                 Figure 8.11 
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Figure 8.12, 8.13, 8.14:  Placental Dkk1 and β-Catenin Analysis.   Whole-tissue Dkk1 mRNA content (Figure 8.12) in 
placentas of Obesity-Resistant (OR) and Obesity-Prone (OP) dams.  Representative image of Dkk1 protein localization in the 
decidual/junctional zones in placentas of OR and OP dams as well as in the labyrinthine zone of placentas of OR and OP dams 
(Figure 8.13). Representative image of β-Catenin protein localization in the decidual/junctional zones in placentas of OR and 
OP dams as well as in the labyrinthine zone of placentas of OR and OP dams (Figure 8.14). Red color represents β-Catenin 
or Dkk1 protein, and blue color represents nuclear staining.  n=10 for mRNA analysis, and n=5 for staining.  Results are 
reported as means ± SEM.  *P<0.01 when compared to OR. 
 
Figure 8.12   Figure 8.13 
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Figure 8.12, 8.13, 8.14 (Continued) 
Figure 8.14 
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Figure 8.15, 8.16, 8.17: DKK1 mRNA and Lipid Content in NEFA-Treated JEG3 Cells. 
DKK1 mRNA content in JEG3 cells following treatment with 400 μmol/L Non-Esterified Fatty Acids (NEFA) (Figure 8.15), 
with a representative images of Oil Red O staining (Figure 8.16 top) in cells following 0 and 400 μmol/L NEFA treatment 
and quantification of the Oil Red O staining (Figure 8.16 bottom), as well as the MDA concentration from TBARS assay 
from the same experiment (Figure 8.17).  n=3 for mRNA and staining analyses.  Results are reported as means ± SEM.  
*P<0.01 when compared to 0 μmol/L treatment. 
 
Figure 8.15             Figure 8.16         Figure 8.17 
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Figure 8.18, 8.19, 8.20, 8.21: DKK1, β-Catenin and Lipid Analysis in NEFA-Treated JEG3 Cells Following Dkk1 
Overexpression.  DKK1 mRNA content following DKK1 overexpression in JEG3 cells treated with 400 μmol/L Non-
Esterified Fatty Acids (NEFA) (Figure 8.18), as well as a representative image of β-Catenin protein localization in WT (wild-
type, following transfection of empty pCMV) and  +Dkk1 (Dkk1-overexpressed) JEG3 cells following treatment with 400 
μmol/L NEFA (Figure 8.19).  Red color represents β-Catenin protein, and blue color represents nuclear staining.  
Representative image of Oil Red O staining in WT and +Dkk1 JEG3 cells following treatment with 400 μmol/L NEFA 
(Figure 8.20, top) and quantification of the Oil Red O staining (Figure 8.20 bottom).  mRNA analysis of +Dkk1 JEG3 cells 
following NEFA treatment (Figure 8.21).  n=3 for mRNA analysis, staining, and Oil Red O quantification. Results are 
reported as means ± SEM.  *P<0.05 when compared to WT cells.  #P<0.01 when compared to WT cells. 
 
Figure 8.18       Figure 8.19 
 
 
 
 
 
65 
Figure 8.18, 8.19, 8.20, 8.21 (Continued) 
Figure 8.20            Figure 8.21 
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Figure 8.22, 8.23, 8.24: Hepatic Triglyceride (TG), Non-Esterified Fatty Acid (NEFA) Measurements and Oil Red O 
Staining in Neonatal Offspring.  Hepatic TG (Figure 8.22), NEFA (Figure 8.23), and Oil Red O staining (Figure 8.24) in 
neonatal offspring of Obesity-Resistant (OR) and Obesity-Prone (OP) dams at the time of cesarean delivery on gestational d21. 
Results are reported as means ± SEM.  n=10 livers.  *P <0.05 when compared to OR. 
 
Figure 8.22       Figure 8.23 
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Figure 8.22, 8.23, 8.24 (Continued) 
 
Figure 8.24 
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Figure 8.25, 8.26: Dkk1 Expression and Histone Modifications in Livers of OR and OP Neonatal Offspring.   Whole-
tissue Dkk1 mRNA content (Figure 8.25) and promoter Chromatin Immunoprecipitation (ChIP) analysis (Figure 8.26) in 
livers of neonatal offspring of Obesity-Resistant (OR) and Obesity-Prone (OP) dams. n=10 livers.  Results are reported as 
means ± SEM.  *P<0.05 when compared to OR. 
 
       Figure 8.25          Figure 8.26 
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Figure 8.27, 8.28: Dkk1 mRNA and Lipid Content in NEFA-Treated H4IIEC3 Cells. 
Dkk1 mRNA content in H4IIEC3 rat hepatocyte cells following treatment with 400 μmol/L Non-Esterified Fatty Acids 
(NEFA) (Figure 8.27), with a representative images of Oil Red O staining (Figure 8.28 top) in cells following 0 and 400 
μmol/L NEFA treatment and quantification of the Oil Red O staining (Figure 8.28 bottom).  n=3 for mRNA and staining 
analyses.  Results are reported as means ± SEM.  *P<0.01 when compared to 0 μmol/L treatment. 
 
Figure 8.27              Figure 8.28 
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APPENDIX A: COMMON RODENT MODELS OF OBESITY 
 
A thorough review of rodent models of diet-induced obesity (DIO), dietary resistance (DR), 
obesity proneness (OP) and obesity resistance (OR) has been made available as a supplemental 
file named Appendix A-Rodent Obesity Models.pdf. 
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APPENDIX B: QUANTITATIVE REAL-TIME PCR DISSOCIATION CURVES 
 
The dissociation (melting) curves for all primers used in the current studies have been 
made available as a supplemental file named Appendix B-qRT-PCR Curves.pdf 
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